MSH3 and Huntington disease: Analyzing MSH3 expression in postmortem brains of HD patients carrying Msh3 variants associated with disease progression hastening or slowing may provide more meaningful insights than relying solely on preclinical models to determine the extent of reduction in somatic CAG repeat expansion, and consequently MSH3 expression, required to achieve therapeutic benefits.